{"id":"W2074595878","doi":"10.1007/s40271-015-0123-2","title":"Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial","year":2015,"lang":"en","type":"article","venue":"Patient","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Cilag; AbbVie Canada; Janssen Canada; Merck Canada; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Rilpivirine; Emtricitabine; Medicine; Regimen; Tolerability; Internal medicine; Randomized controlled trial; Ritonavir; Lamivudine; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Pharmacology; Adverse effect; Viral load; Virology; Virus; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004007169,0.000879473,0.002013604,0.0003252919,0.0003202772,0.0007002231,0.0006174878,0.001272338,0.002900205],"category_scores_gemma":[0.003421517,0.0003135076,0.002491424,0.00037724,0.0006005284,0.0009264717,0.0003888325,0.001882797,0.0003071299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004916085,"about_ca_system_score_gemma":0.0004493395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004046423,"about_ca_topic_score_gemma":0.0007167264,"domain_scores_codex":[0.9978563,0.001378347,0.000188167,0.000252457,0.0001582317,0.0001664478],"domain_scores_gemma":[0.9966868,0.001085419,0.001181246,0.0002837801,0.0001607315,0.0006020091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950394,0.01062569,0.00936728,0.0003774298,0.002272477,0.00003569072,0.00009277114,0.0004294627,0.001349406,0.00003313872,0.0003081532,0.0247145],"study_design_scores_gemma":[0.5756955,0.3607176,0.05729466,0.00007840538,0.002920856,0.00009829587,0.000111011,0.001126263,0.001216529,0.0001846049,0.000509934,0.00004633631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99797,0.0008607412,0.00008283764,0.00006083653,0.00004369985,0.000301996,0.0003084359,0.00001184169,0.0003596967],"genre_scores_gemma":[0.9981035,0.0003457072,0.0002210287,0.0001258643,0.00008502252,0.0004294306,0.0004637424,0.000002469201,0.0002232331],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004007169,"threshold_uncertainty_score":0.02119225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03556670404832139,"score_gpt":0.2744014148754535,"score_spread":0.2388347108271321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}